Fig. 8

Activation of hippocampal GPR17 induced cognitive impairment in normal mice. A Experimental procedure for the test schedule. MDL-29951 was microinfused into bilateral DG regions of the hippocampus of mice, followed by LPS (0.25 mg/kg, i.p.) or its vehicle was administered 7 days after the MDL-29951 infusions 3 weeks, and then, the OFT, MWM, and NOR tests were conducted in mice. B Representative immunoreactive bands of GPR17 protein in the hippocampus. GPR17 protein (C) and mRNA levels (D) in the hippocampus, n = 4 mice/group. E Total distance in the OFT. F During the 2-day visible platform test, there were no differences in the escape latency among all groups in the MWM test. Escape latency was changed on the hidden platform during the 3-day acquisition trials. G Time spent in the target quadrant during the probe trial test. H Number of platform crossings during the probe trial test. I Swimming speed among all groups during probe testing on day 6. J Discrimination index of the NOR test. Values shown are expressed as mean ± SEM; n = 12 mice/group. *P < 0.05, **P < 0.01, ***P < 0.001